Skip to content

Author

H. Nagashima

We have 14 of 64 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Cancer of Unknown Primary in Transition: From Empirical Chemotherapy to Immunotherapy and Molecularly Guided Treatment.

This narrative review synthesizes contemporary evidence and proposes a practical four-layer algorithm in which clinical urgency, tissue and biomarker readiness, and precision opportunities are assessed in parallel to preserve treatment opportunities.

T. Sagawa, Masahiro Hirakawa, H. Nagashima et al. · 0 citations
Review Sep 2026

Beyond Zolbetuximab: Next-Generation Targeting Strategies for CLDN18.2

Current evidence through July 2026 is summarized, plausible mechanisms of resistance and biomarker evolution are examined, and a cautious, modality-specific framework for future clinical development is proposed.

T. Sagawa, H. Nagashima, K. Fujikawa · 0 citations
Review Aug 2026

BRAF V600E-Mutated Metastatic Colorectal Cancer: Practical Management in the Post-BREAKWATER Era

Treatment selection in the post- BREAKWATER era should integrate molecular context, patient fitness, and remaining evidence gaps, as well as the management of frail or oxaliplatin-ineligible patients, maintenance therapy, local treatment integration, and sequencing after frontline encorafenib exposure.

T. Sagawa, H. Nagashima, K. Fujikawa · 0 citations
Review Sep 2026

Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V

The development of MRTX1133, zoldonrasib, zoldonrasib (RMC-9805), VS-7375, RMC-5127, and daraxonrasib (RMC-6236) demonstrates that direct targeting of previously undruggable KRAS alleles is becoming clinically feasible, and anti-EGFR combination strategies particularly important in CRC.

T. Sagawa, Masahiro Hirakawa, H. Nagashima et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.